Product Highlight - Spikevax XBB.1.5

21 Mar 2024
Product Highlight - Spikevax XBB.1.5

The newly available mRNA booster vaccine for individuals aged ≥12 years1

  • Substantial antibody response against SARS-CoV-2 XBB.1.5*1
    - A 16.7-fold (95% CI [Confidence Interval], 12.8-21.7)† increase in antibody level at Day 15 compared to pre-boost
  • Tolerable safety profile1
    - Most common adverse reactions include injection-site pain, fatigue, myalgia and headache
  • Simple administration1
    - Intramuscular injection
    - Pre-filled syringe

*The safety and immunogenicity of a booster dose of spikevaxTM XBB.1.5 are evaluated in an ongoing phase II/III open-label study in human adult participants (n=50).1
†Geometric mean fold rise (GMFR) at Day 15 relative to GMFR at pre-booster in all participants.

Reference:
1. spikevaxTM XBB.1.5 Hong Kong Prescribing Information. November 2023.

This product information is for reference and use by healthcare professionals.
HK-COV-2400007


MODERNA HONG KONG LTD
One Pacific Place, 88 Queensway, Hong Kong
Email: media@modernatx.com; Website: www.modernatx.com

Related MIMS Drugs